BS_BVSW4GTG
medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- medulloblastoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- medulloblastoma
- overall_survival_months
- 37.81208935611038
- age_years
- 0.318
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.687
- G2M_CHECKPOINT+0.608
- MYC_TARGETS_V1+0.506
- MYC_TARGETS_V2+0.428
- MITOTIC_SPINDLE+0.364
- SPERMATOGENESIS+0.254
- PANCREAS_BETA_CELLS+0.225
- UNFOLDED_PROTEIN_RESPONSE+0.212
- HEDGEHOG_SIGNALING+0.094
- DNA_REPAIR+0.078
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.586
- INTERFERON_GAMMA_RESPONSE-0.534
- INFLAMMATORY_RESPONSE-0.474
- ALLOGRAFT_REJECTION-0.462
- IL6_JAK_STAT3_SIGNALING-0.459
- ANGIOGENESIS-0.456
- TNFA_SIGNALING_VIA_NFKB-0.432
- IL2_STAT5_SIGNALING-0.385
- XENOBIOTIC_METABOLISM-0.374
- COMPLEMENT-0.368
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_45J79YTF | high-grade glioma | — | 0.961 |
| 2 | BS_RD4D5F9F | medulloblastoma | — | 0.959 |
| 3 | BS_7XQRH69M | medulloblastoma | — | 0.956 |
| 4 | BS_1AYRM596 | medulloblastoma | — | 0.955 |
| 5 | BS_7C40TRCY | medulloblastoma | — | 0.953 |
| 6 | BS_AM70R8RG | medulloblastoma | — | 0.953 |
| 7 | BS_3F5PR9GS | medulloblastoma | — | 0.953 |
| 8 | BS_BPWEFR89 | medulloblastoma | — | 0.951 |
| 9 | BS_81SP2HX4 | medulloblastoma | — | 0.951 |
| 10 | BS_AMZ70B6F | medulloblastoma | — | 0.945 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.687 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.608 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.506 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.428 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.364 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.254 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.225 | Cobimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.212 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.094 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.078 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.035 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.012 | Inavolisib | — uncovered |